antibeta References
Selected Literature on NAbs, NAb Assays and Immunogenicity of Therapeutic Proteins
Bellomi F, Scagnolari C, Tomassini V et al. (2003). Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 215:3-8.
Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R (2000). Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48:95-100.
Bertolotto A, Malucchi S, Sala A et al. (2002). Differential effects of three interferon betas on neutralizing antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148-153.
Bertolotto A, Gilli F, Sala A et al. (2003) Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60:634-639.
Deisenhammer F, Schellekens H, Bertolotto A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J. Neurol. 2004 Jun;251 Suppl 2:II31-9. Review.
Grossberg SE, Kawade Y, Kohase M, Klein JP (2001). The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 21:743-755.
Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N, (2001). The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 21:729-742.
Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, Richards SM, Rup B, Shores E, Swanson SJ, Wakshull E. (2007). Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 321:1-18.
Kappos L, Clanet M, Sandberg-Wolheim M et al. (2005). Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65:40-47.
Kawade Y. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titre. J Interferon Res 1980;1:61-70.
Kivisakk P, Alm GV, Fredrikson S, Link H (2000). Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol 7:27-34.
Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004 Jun 8;62(11):2031-7.
Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology. 2003 Nov 11;61(9 Suppl 5): S24-6. Review.
Pachner AR, Narayan K, Price N, Hurd M, Dail D (2004). MxA Gene Expression Analysis as an Interferon-beta Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity. Mol Diagn 7:17-25.
Polman C, Kappos L, White R et al. (2003a). Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60:37-43.
Schellekens H, Casadevall N. Immunogenicity of biopharmaceuticals. The European perspective. DevBiol (Basel). 2003;112:23-8.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003 Oct 11;362(9391):1184-91.